Reuters logo
BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​
October 30, 2017 / 6:14 AM / 20 days ago

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

Oct 30 (Reuters) - ARGENX NV:

* ‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​

* ‍PHASE I CLINICAL TRIAL WILL ENROLL UP TO 32 HEALTHY VOLUNTEERS​

* ‍TOPLINE DATA FOR MYASTHENIA GRAVIS AND IMMUNE THROMBOCYTOPENIA EXPECTED IN Q1 AND SECOND HALF OF 2018

* ‍INTERIM RESULTS FROM PEMPHIGUS VULGARIS TRIAL EXPECTED DURING SECOND HALF OF 2018 ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below